Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07611110CT.gov AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) | — | Recruiting | — | — | — |
NCT07287150CT.gov A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07241416CT.gov A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT07028853CT.gov This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | — | Recruiting | — | — | — |
NCT06922318CT.gov The COSMYC Trial (COmbined Suppression of MYC) | — | Recruiting | — | — | — |
NCT07086651CT.gov A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) | — | Completed | — | — | — |
NCT06764485CT.gov A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06691984CT.gov Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | — | Active Not Recruiting | — | — | — |
NCT06228053CT.gov Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06629779CT.gov A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | — | Recruiting | — | — | — |
Show 76 more trialsShow fewer
NCT06992232CT.gov Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC | — | Recruiting | — | — | — |
NCT06520345CT.gov The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | — | Recruiting | — | — | — |
NCT06582628CT.gov Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) | — | Recruiting | — | — | — |
NCT06320067CT.gov A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06430411CT.gov Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | — | Not Yet Recruiting | — | — | — |
NCT06312670CT.gov Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT06136624CT.gov Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | — | Recruiting | — | — | — |
NCT06120491CT.gov Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | — | Active Not Recruiting | — | — | — |
NCT05404139CT.gov Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) | — | Recruiting | — | — | — |
NCT06702995CT.gov Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT05751941CT.gov Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05701007CT.gov Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | — | Completed | — | — | — |
NCT05683964CT.gov Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | — | Active Not Recruiting | — | — | — |
NCT05588609CT.gov Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | — | Terminated | — | — | — |
NCT05457257CT.gov Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | — | Active Not Recruiting | — | — | — |
NCT05367440CT.gov Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT05413421CT.gov Study of ORIC-944 in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05081193CT.gov Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT05204927CT.gov 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT05011188CT.gov FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04986423CT.gov ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04335682CT.gov Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | — | Completed | — | — | — |
NCT04844749CT.gov Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent | — | Terminated | — | — | — |
NCT04729114CT.gov A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT03709550CT.gov Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT03850795CT.gov HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | — | Terminated | — | — | — |
NCT04647526CT.gov Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | — | Active Not Recruiting | — | — | — |
NCT04631601CT.gov Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | — | Terminated | — | — | — |
NCT04446117CT.gov Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | — | Active Not Recruiting | — | — | — |
NCT04332744CT.gov Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | — | Completed | — | — | — |
NCT04419402CT.gov Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer | — | Unknown | — | — | — |
NCT04237584CT.gov A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients | — | Terminated | — | — | — |
NCT03999515CT.gov Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | — | Terminated | — | — | — |
NCT04262154CT.gov Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04179864CT.gov A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer | — | Terminated | — | — | — |
NCT04116775CT.gov Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | — | Unknown | — | — | — |
NCT04104776CT.gov A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | — | Recruiting | — | — | — |
NCT04076059CT.gov An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | — | Active Not Recruiting | — | — | — |
NCT03751436CT.gov Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03939689CT.gov I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). | — | Completed | — | — | — |
NCT03903835CT.gov ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT03770455CT.gov Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | — | Terminated | — | — | — |
NCT03344211CT.gov Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03568656CT.gov Study to Evaluate CCS1477 in Advanced Tumours | — | Completed | — | — | — |
NCT03110588CT.gov Phase I Trial of PACE for Metastatic Prostate Cancer | — | Withdrawn | — | — | — |
NCT03437941CT.gov Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03314324CT.gov A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer | — | Completed | — | — | — |
NCT03295565CT.gov Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | — | Completed | — | — | — |
NCT03016741CT.gov Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02987543CT.gov Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | — | Completed | — | — | — |
NCT02935205CT.gov Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | — | Unknown | — | — | — |
NCT03123978CT.gov Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02711956CT.gov A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02861573CT.gov Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | — | Recruiting | — | — | — |
NCT02740985CT.gov A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | — | Completed | — | — | — |
NCT02677896CT.gov A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | — | Completed | — | — | — |
NCT02500901CT.gov Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | — | Terminated | — | — | — |
NCT02532114CT.gov Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT02607228CT.gov Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02555189CT.gov Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | — | Terminated | — | — | — |
NCT02384382CT.gov A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) | — | Completed | — | — | — |
NCT02485691CT.gov Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent | — | Completed | — | — | — |
NCT02507570CT.gov Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis | — | Completed | — | — | — |
NCT02491411CT.gov Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | — | Terminated | — | — | — |
NCT02522715CT.gov Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02815033CT.gov Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide | — | Completed | — | — | — |
NCT02379390CT.gov Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide | — | Terminated | — | — | — |
NCT02407054CT.gov A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer | — | Completed | — | — | — |
NCT02814968CT.gov PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide | — | Completed | — | — | — |
NCT02125357CT.gov Sequencing Abiraterone and Enzalutamide in mCRPC | — | Completed | — | — | — |
NCT02116582CT.gov A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01942837CT.gov Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT01981122CT.gov A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01663415CT.gov A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT01650194CT.gov A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients | — | Completed | — | — | — |
NCT01606982CT.gov Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enzalutamide (this asset) | AstraZeneca | Approved | BB · 67 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Enzalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P4 | BBB · 73 |
| Prostate Carcinoma | — | P4 | BBB · 73 |
| Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enzalutamide in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enzalutamide-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →